Checkpoint Therapeutics said on Monday the U.S. Food and Drug Administration had declined to approve its experimental therapy to treat a form of skin cancer following an.
Replimune Group said on Tuesday its experimental combination therapy to treat a common form of skin cancer failed to significantly remove or reduce cancerous lesions in a midstage study.
The antibody-drug conjugate tisotumab vedotin led to improved outcomes compared with chemotherapy in second- or third-line treatment of recurrent/metastatic cervical cancer.